| A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling R Székely, F Wáczek, I Szabadkai, G Németh, B Hegymegi-Barakonyi, ... Immunology letters 116 (2), 225-231, 2008 | 102 | 2008 |
| Signal transduction therapy with rationally designed kinase inhibitors G Keri, L Orfi, D Eros, B Hegymegi-Barakonyi, C Szantai-Kis, Z Horvath, ... Current Signal Transduction Therapy 1 (1), 67-95, 2006 | 67 | 2006 |
| Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs L Orfi, F Wáczek, J Pató, I Varga, B Hegymegi-Barakonyi, RA Houghten, ... Current medicinal chemistry 11 (19), 2549-2553, 2004 | 52 | 2004 |
| Signalling inhibitors against Mycobacterium tuberculosis-early days of a new therapeutic concept in tuberculosis B Hegymegi-Barakonyi, R Szekely, Z Varga, R Kiss, G Borbely, G Nemeth, ... Current medicinal chemistry 15 (26), 2760-2770, 2008 | 47 | 2008 |
| Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives Z Székelyhidi, J Pató, F Wáczek, P Bánhegyi, B Hegymegi-Barakonyi, ... Bioorganic & medicinal chemistry letters 15 (13), 3241-3246, 2005 | 47 | 2005 |
| Drug discovery in the kinase inhibitory field using the nested chemical library™ technology G Kéri, Z Székelyhidi, P Bánhegyi, Z Varga, B Hegymegi-Barakonyi, ... Assay and drug development technologies 3 (5), 543-551, 2005 | 43 | 2005 |
| Tyrosine kinase inhibitors-small molecular weight compounds inhibiting EGFR. B Hegymegi-Barakonyi, D Eros, C Szantai-Kis, N Breza, P Bánhegyi, ... Current Opinion in Molecular Therapeutics 11 (3), 308-321, 2009 | 29 | 2009 |
| Structure-Activity Relationships of PDE5 Inhibitors (Supporting Material) D Eros, C Szantai-Kis, R Kiss, G Keri, B Hegymegi-Barakonyi, I Kovesdi, ... Current medicinal chemistry 15 (16), 1570-1585, 2008 | 24 | 2008 |
| Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor J Pato, G Keri, L Orfi, F Waczek, Z Horvath, P Banhegyi, I Szabadkai, ... US Patent App. 10/715,591, 2004 | 24* | 2004 |
| Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models M Tejeda, D Gaal, L Hullan, B Hegymegi-Barakonyi, GY Keri Anticancer research 26 (5A), 3477-3483, 2006 | 22 | 2006 |
| Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases N Breza, J Pato, L ŐRFI, B Hegymegi-Barakonyi, P Banhegyi, E Varkondi, ... Journal of Receptors and Signal Transduction 28 (4), 361-373, 2008 | 10 | 2008 |
| Pro‐Apoptotic and Anti‐Apoptotic Molecules Affecting Pathways of Signal Transduction G Keri, G Racz, K Magyar, L Örfi, A Horváth, R Schwab, BB HEGYMEGI, ... Annals of the New York Academy of Sciences 1010 (1), 109-112, 2003 | 9 | 2003 |
| [Pyrido [2, 3-b] pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction]. L Kékesi, A Sipos, G Németh, A Dancsó, E Illyés, S Boros, N Breza, ... Acta Pharmaceutica Hungarica 84 (3), 91-104, 2014 | 4 | 2014 |
| New Method for the Synthesis of 2-Acylamino-1-benzothiophene-3-carboxamide Derivatives from the Corresponding Esters P Banhegyi, F Waczek, Z Szekelyhidi, B Hegymegi-Barakonyi, G Kéri, ... Synthetic Communications® 38 (19), 3270-3276, 2008 | 4 | 2008 |
| Application of Kohonen Self-Organizing feature maps in QSAR of human ADMET and kinase data sets B Hegymegi-Barakonyi, L Orfi, G Kéri, I Kövesdi Acta Pharmaceutica Hungarica 83 (4), 143-148, 2013 | 1 | 2013 |
| Új eljárás savamidok elöállítására, alacsony reaktivitású észterekböl: 2-acilamino-1-benzotiofén-3-karboxamid származékok elöállítása P BANHEGYI, F WACZEK, Z SZEKELYHIDI, B HEGYMEGI-BARAKONYI, ... Acta pharmaceutica hungarica 78 (2), 75-78, 2008 | 1 | 2008 |
| NESTED CHEMICAL LIBRARY OF KINASE INHIBITORS AND PHARMACOPHORE MODELLING G Keri, G Boekoenyi, F Waczek, Z Greff, D Eros, C Szantai-Kis, ... JOURNAL OF PEPTIDE SCIENCE 10, 249-249, 2004 | 1 | 2004 |
| Mycobacterium tuberculosis ellenes hatoanyagok fejlesztese es szerkezet-hatas osszefuggeseinek vizsgalata. F Baska, ER Szekely, C Szantai-Kis, P Banhegyi, B Hegymegi-Barakonyi, ... | | 2013 |
| Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis F Baska, ER Székely, C Szántai-Kis, P Bánhegyi, B Hegymegi-Barakonyi, ... Acta Pharmaceutica Hungarica 83 (3), 88-95, 2013 | | 2013 |
| Synthetic lethality screens of vichem compounds in P53 mutant syngenic cell line models B Hegymegi-Barakonyi, G Kéri, L Őrfi, Z Varga, Z Greff, Z Horváth, B Jóri, ... Zeitschrift für Gastroenterologie 46 (05), A30, 2008 | | 2008 |
Dániel ErősVerified email at vichem.hu
Dániel ErősVerified email at vichem.hu